|
Categories
Pharmaceutical Company
Pharmaceutical Sales
Pharmaceutical
Distributor
Pharmaceutical
Preparation
Pharmaceutical
Jobs
Pharmaceutical
Industry
Pharmaceutical
Drug
Pharmaceutical
Sales Jobs
Pharmaceutical
Product
Pharmaceutical
News
Pharmaceutical
Research
Pharmaceutical
Manufacturer
Pharmaceutical Sales
Rep
Pharmaceutical
Sales Resume
Pharmaceutical
Online
Pharmaceutical
Marketing
Pharmaceutical
Dictionary
Pharmaceutical
Recruiter
Pharmaceutical
Supply
Pharmaceutical
Technology
Pharmaceutical
Advertising
Pharmaceutical
Schools
Companies
Pfizer Pharmaceutical
Wyeth Pharmaceutical
Watson Pharmaceutical
Merck Pharmaceutical
Roche Pharmaceutical
King Pharmaceutical
Teva Pharmaceutical
Aventis
Pharmaceutical
Novartis
Pharmaceutical
Forest
Pharmaceutical
Tap
Pharmaceutical
Shire
Pharmaceutical
Mayne
Pharmaceutical
Millennium
Pharmaceutical
Lilly
Pharmaceutical
Mylan
Pharmaceutical
Kos
Pharmaceutical
Takeda
Pharmaceutical
Endo
Pharmaceutical
Janssen
Pharmaceutical
Barr
Pharmaceutical
Abbott
Pharmaceutical
Reliant
Pharmaceutical
Solvay
Pharmaceutical
Amylin
Pharmaceutical
Vertex
Pharmaceutical
Osi
Pharmaceutical
Bayer
Pharmaceutical
Voyager
Pharmaceutical
Mcneil
Pharmaceutical
Boehringer
Ingelheim
Astra
Zeneca Pharmaceutical
Glaxosmithkline
Pharmaceutical
Novo Nordisk
Pharmaceutical
3m
Pharmaceutical
Eli
Lilly Pharmaceutical
Elan Pharmaceutical
Ivax
Pharmaceutical
Search engines:
Google
Lycos
AltaVista
Yahoo
Mirago
Ask
Teoma
Excite |
|
|
|
Millenium Pharmaceuticals
Millenium
Pharmaceuticals
Millenium Pharmaceuticals was founded in 1993 with a
vision that still drives the Company today. Millenium Pharmaceuticals believes
that by applying the methods of leading science to the art of drug discovery,
they will develop breakthrough products that will fundamentally change the
practice of medicine.
In its early years, Millenium Pharmaceuticals
focused on building top-notch science and business teams to help achieve this
vision. Attracted by their scientific leadership, entrepreneurial spirit, and
aggressive but judicious growth, Millenium Pharmaceuticals quickly began to
earn the attention and respect of many of the best scientists and business
people from around the world.
Beginning in 1994, Millenium
Pharmaceuticals created more than 20 strategic alliances with leading
pharmaceutical and biotechnology companies. These alliances provided Millenium
Pharmaceuticals with close to $2 billion of committed funding that was used to
develop and enhance their pipeline. With an innovative, integrated science and
technology platform, expertise in drug-target discovery, and industry-leading
partnerships, the company was geared to prime the product pipeline.
But
Millennium leadership also recognized that discovering new drug targets was
only one step in the pathway toward the ultimate goal of providing breakthrough
therapeutic products that would help patients. Through transformational mergers
and acquisitions, Millennium continued to advance toward the goal of building a
leading biopharmaceutical company. A merger with Leukosite in 1999 brought the
company its first drug close to market, Campath® (alemtuzumab) Injection,
and additional investigational drugs in clinical trials. In 2000, a merger with
Cambridge Discovery Chemistry gave Millennium a strong presence in the United
Kingdom and added to the organization more than 100 scientists with expertise
in chemistry. In a strategic business decision, Campath was later sold to
Genzyme.
In February 2002, a merger with COR Therapeutics — among
the largest such mergers in the history of the biotech industry — helped
to further solidify Millenium Pharmaceuticals standing as a leading
biopharmaceutical company. In addition to creating a strong pipeline of novel
therapeutics, the merger added cardiovascular research and drug development to
the Company's other key therapeutic areas: oncology and inflammation. The
merger also brought INTEGRILIN® (eptifibatide) Injection, a market-leading
intravenous anti-platelet drug for patients with severe cardiovascular
diseases, into the Millennium fold. Later in 2005, the Company sold the rights
to Schering-Plough.
As Millennium celebrated its tenth anniversary in
2003, the Company reached new heights. VELCADE® (bortezomib) for Injection
was launched in May for the treatment of relapsed and refractory multiple
myeloma. VELCADE is now approved in the U.S. for treatment of multiple myeloma
patients after only one prior therapy. VELCADE — the first FDA approved
proteasome inhibitor reached the market in record time and represents the first
treatment in more than a decade to be approved for patients with multiple
myeloma — a cancer of the blood.
VELCADE® is currently approved
in more than 75 countries worldwide, including the U.S., European Union and a
number of countries within Latin America and Southeast Asia. VELCADE is being
co-developed by Millennium Pharmaceuticals, Inc. and Johnson & Johnson
Research and Development L.L.C. Millennium is responsible for commercialization
of VELCADE in the U.S. Ortho Biotech Products L.P. and the Janssen-Cilag group
of companies are responsible for commercialization in the EU and the rest of
the world. Janssen Pharmaceutical K.K. is responsible for Japan.
Today,
Millennium has a leading oncology product, proven commercial capabilities, and
many product candidates in varying stages of development. We are continually
evolving to ensure that our research and development efforts stay current with
the demand for new therapeutic products that will make a genuine difference in
patient's lives.
www.mlnm.com/ |
|
|
|
|
